Ascendis Pharma announced that the FDA has accepted and granted Priority Review status for TransCon PTH for the treatment of adult patients with hypoparathyroidism, with
On November 1, Rhythm Pharmaceuticals announced that its MC4R agonist setmelanotide was granted Breakthrough Therapy Designation by the FDA for the treatment of hypothalamic obesity.
Foreword Chimeric antigen receptor (CARs)-based T-cell therapy has shown great success against blood cancers; however, potential lethal toxicity (eg, cytokine release syndrome) and high cost
On October 31, Actinium Pharmaceuticals announced that the pivotal Phase III SIERRA study of its CD45 monoclonal antibody Iomab-B (apamistamab) in patients with relapsed or
On October 31, ESSA Pharma announced that Johnson & Johnson/Janssen Pharmaceuticals will discontinue a Phase I combination therapy clinical study of its lead candidate, EPI-7386,
Minerva Neurosciences is a biopharmaceutical company focused on developing therapies for diseases of the central nervous system (CNS). Recently, the company announced that it received
In the field of biological scientific research, you often come into contact with the little thing called plasmid, and when you find the map of
The conjugation of Linker-drug (LD) to antibodies is a critical step in the generation of ADCs and the determination of key quality attributes of ADCs
On October 27, Gilead announced its Q3 financial report and revealed that its marketing application for bulevirtide (trade name: Hepcludex) for the treatment of chronic
On October 27, Merck announced its third-quarter financial report, and its product pipeline no longer includes the oncolytic virus therapy Cavatak (V937) obtained from the
Gilead Sciences recently announced the real-world data (RWD) of the three-in-one compound new drug Biktarvy BICSTaR study at the 30th International Conference on Drug Therapy
On October 26, ESSA Pharma announced the latest positive results from the first two cohorts of the company’s lead drug candidate EPI-7386 in combination with
